Does Centene Corporation Cover Vyvanse?

What Is Centene Corporation and Which Plans Does It Run?

Centene Corporation is one of the largest managed-care organizations in the United States, serving more than 28 million members as of its 2024 annual report. It operates across Medicaid, Medicare Advantage, Medicare Prescription Drug Plans (PDPs), and Affordable Care Act (ACA) marketplace plans in most states.

Key Plan Brands Under the Centene Umbrella

Understanding which sub-brand administers your plan matters because each subsidiary may maintain a slightly different formulary.

• Ambetter Health handles ACA marketplace plans in roughly 30 states.
• WellCare covers Medicare Advantage and Part D prescription drug plans nationally.
• Sunshine Health serves Florida Medicaid members.
• Peach State Health Management covers Georgia Medicaid.
• Coordinated Care operates in Washington State Medicaid.
• IlliniCare Health covers Illinois Medicaid.

Each subsidiary files its own formulary with CMS or the state Medicaid agency. That means a WellCare Medicare plan in Ohio may place Vyvanse on a different tier than Ambetter's marketplace plan in Texas. Always pull the current formulary PDF from your plan's member portal before calling your prescriber.

Why Formulary Position Matters for Out-of-Pocket Cost

Formulary tier directly determines your copay or coinsurance. On a typical Centene Ambetter Silver plan, Tier 3 branded drugs carry a $50, $75 copay per 30-day supply before the deductible is met, while Tier 4 specialty drugs may require 20 to 40% coinsurance. Because Vyvanse held brand-only status until the FDA approved the first generic lisdexamfetamine dimesylate in 2023 [1], it historically landed in high-cost tiers. Generic entry has begun to shift that positioning on some formularies.

What Is Vyvanse and Why Is It Prescribed?

Vyvanse (lisdexamfetamine dimesylate) is a prodrug of d-amphetamine. The FDA first approved it in 2007 for ADHD in children ages 6 to 12, later expanded to adults with ADHD, and again in 2015 for moderate-to-severe binge eating disorder (BED) in adults [2]. It is classified as a Schedule II controlled substance under the Controlled Substances Act, which introduces additional prescribing and dispensing restrictions that can affect insurance processing.

Approved Indications That Support a Coverage Claim

Vyvanse carries two FDA-approved indications: ADHD (ages 6 and older) and BED (adults). Both are recognized conditions under the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). Because these are established medical diagnoses with documented impairment criteria, prescribers have a factual basis for prior authorization documentation.

The 2019 American Academy of Pediatrics (AAP) Clinical Practice Guideline for ADHD recommends stimulant medication as first-line pharmacotherapy for children 6 years and older with ADHD [3]. For adults, the FDA label for Vyvanse in ADHD was supported by two placebo-controlled trials showing statistically significant reductions in ADHD Rating Scale scores (P<0.001 in the key adult study) [2].

The BED Indication and Why It Changes the Coverage Conversation

BED is the most common eating disorder in the United States, affecting an estimated 2.8 million adults according to the National Eating Disorders Association. The FDA-approved BED trials for Vyvanse (Study 1 and Study 2, each N=260 and N=255 respectively) showed a median reduction from approximately 4.4 to 0.8 binge eating days per week vs. Placebo (P<0.001) [4]. Insurers who might otherwise deny an ADHD claim may face a different clinical argument when the prescriber documents a BED diagnosis. Make sure your prescriber specifies the ICD-10 code (F50.81 for BED) on the prior authorization form when that is the diagnosis driving the prescription.

Does Centene Cover Vyvanse on Its Formularies?

The short answer is yes, Centene subsidiaries generally include Vyvanse or its generic lisdexamfetamine on their formularies, but coverage is conditional.

Commercial and Marketplace Plans (Ambetter)

On Ambetter commercial plans, Vyvanse appears on most state formularies at Tier 3 or Tier 4. Prior authorization is required universally. The typical clinical criteria Centene applies to Ambetter plans include:

1. A documented DSM-5 diagnosis of ADHD or BED from a licensed prescriber.
2. Evidence that the patient is 6 years of age or older (ADHD) or an adult (BED).
3. Confirmation that generic stimulant alternatives were tried first OR a clinical rationale for why they were not appropriate (for example, documented intolerance, contraindication, or inadequate response to amphetamine salts and methylphenidate).

Step therapy requirements vary by state because several states have enacted "step therapy override" laws. California, New York, Texas, and more than 25 other states have statutes requiring insurers to grant step therapy exceptions when a prescriber documents that the required first-line drug is clinically inappropriate [5]. If your state has such a law, your prescriber can invoke it to bypass the generic-first requirement.

Medicare Plans (WellCare Part D)

This is where Vyvanse coverage becomes more complicated. Schedule II stimulants are not excluded from Medicare Part D by statute. However, the CMS formulary review process means individual WellCare Part D plans vary in their Vyvanse tier placement. In 2024, some WellCare Medicare Part D plans listed lisdexamfetamine as a covered Tier 4 specialty drug. Others required prior authorization plus quantity limits (for example, 30 capsules per 30 days, which aligns with the standard dispensing limit for Schedule II drugs).

The CMS Medicare Prescription Drug Benefit manual specifies that all Part D plans must cover drugs in certain protected classes, but ADHD medications are not currently in one of the six protected classes (oncology, anticonvulsants, immunosuppressants, antidepressants, antipsychotics, antiretrovirals) [6]. That means WellCare has some formulary flexibility, and coverage cannot be assumed.

Medicaid Plans (Sunshine Health, Peach State, IlliniCare, and Others)

Medicaid formularies are the most restrictive setting for Vyvanse. State Medicaid agencies set preferred drug lists (PDLs), and Centene's managed Medicaid plans must generally comply with the state PDL.

Key patterns across Centene Medicaid subsidiaries:

• Generic-first mandate: Most state PDLs require a trial of generic mixed amphetamine salts (Adderall generic) or methylphenidate before approving a branded or higher-tier stimulant. This is a standard utilization management tool consistent with state Medicaid cost-containment goals.
• Age limits: Some state Medicaid programs restrict stimulant coverage to members under age 65 or impose shorter initial authorization periods (90 days) for adults.
• Quantity limits: Medicaid plans routinely cap stimulant dispensing at a 30-day supply per fill, consistent with Drug Enforcement Administration (DEA) rules for Schedule II substances [7].

A 2021 study published in Psychiatric Services found that Medicaid formulary restrictions on brand-name ADHD medications were associated with higher rates of treatment discontinuation, suggesting these policies carry real clinical consequences [8].

How to Get Prior Authorization Approved for Vyvanse Through Centene

Prior authorization (PA) is not a denial. It is a documentation request. Most PA requests for Vyvanse are approved on first submission when the prescriber submits complete records.

Step 1: Confirm the Formulary Status Before Starting

Pull the current formulary for your specific plan from the CMS Drug Formulary Finder (for Medicare) or your plan's member portal. Verify Vyvanse or lisdexamfetamine is listed, and note the tier, any quantity limits, and whether PA is required. This single step prevents most surprises at the pharmacy.

Step 2: Have Your Prescriber Submit the PA With Complete Documentation

The PA form should include:

• ICD-10 diagnosis code (F90.0, F90.9 for ADHD; F50.81 for BED)
• Previous stimulant trials (drug name, dose, duration, reason for discontinuation)
• Functional impairment documentation (school, work, or daily living impact)
• Target symptoms and treatment goals
• For BED: binge frequency data and any prior behavioral therapy

Incomplete PA forms are the leading cause of first-pass denials, according to the American Medical Association's 2023 Prior Authorization Survey, which found that 94% of physicians report PA delays in care and 80% report PA-related care abandonment [9].

Step 3: If Denied, File a Peer-to-Peer Review Request Within 48 Hours

When a PA is denied, the prescriber has the right to request a peer-to-peer review with the plan's medical director. Studies show peer-to-peer reviews reverse initial stimulant PA denials at meaningful rates, particularly when the prescriber documents a specific adverse reaction to the preferred generic.

Step 4: File a Formal Appeal if the Peer-to-Peer Fails

Under the ACA, marketplace plan members have the right to an internal appeal and then an independent external review. Medicare Part D members have similar rights under CMS regulations, with a standard appeal decision required within 7 days (or 72 hours for expedited cases) [6]. Medicaid members can request a State Fair Hearing, which is a federally protected right under 42 CFR Part 431.

The Mental Health Parity and Addiction Equity Act (MHPAEA) is a powerful appeal tool. MHPAEA prohibits health plans from applying more restrictive prior authorization or step therapy requirements to mental health conditions (including ADHD) than they apply to analogous medical/surgical conditions [10]. If a plan requires step therapy for ADHD stimulants but not for comparable chronic-disease medications, that asymmetry is a potential MHPAEA violation. Attorneys and patient advocates have successfully used this argument to overturn insurer restrictions on mental health drugs.

What Does Vyvanse Cost Without Centene Coverage?

Knowing the cash price gives you a baseline for negotiating or using assistance programs.

Retail Cash Prices

Without insurance, brand-name Vyvanse typically costs $350, $450 for a 30-day supply of 70 mg capsules at major retail pharmacies as of early 2025. Generic lisdexamfetamine dimesylate (approved by FDA in 2023) [1] has reduced the uninsured cash price significantly. GoodRx and similar discount programs offer generic lisdexamfetamine at $40, $80 per 30-day supply at many pharmacies. This price differential means that if Centene places Vyvanse on a high tier with 40% coinsurance, the generic with a discount card may cost less out-of-pocket than the insured brand.

Takeda's Patient Assistance and Savings Programs

Takeda, the manufacturer of Vyvanse, offers:

• Vyvanse Savings Card: Eligible commercially insured patients may pay as little as $30 per month. This card is not valid for Medicare, Medicaid, or other federal/state programs.
• Takeda Patient Assistance Program (TAP): Uninsured or underinsured patients who meet income criteria may receive Vyvanse at no cost. Applications are processed through Takeda's patient support line.

These programs do not interact with Centene's PA requirements. A patient can receive approval through PA and still use the savings card to reduce their copay on eligible commercial plans.

Alternatives Centene Is More Likely to Cover Without Prior Authorization

If Vyvanse PA is taking time or has been denied, these FDA-approved ADHD medications are more commonly placed on preferred tiers across Centene formularies.

Generic Stimulant Options

• Mixed amphetamine salts (generic Adderall): First-line on most Centene Medicaid PDLs. Available as immediate-release (IR) and extended-release (XR) formulations. FDA-approved for ADHD in children age 3 and older (IR) and age 6 and older (XR) [11].
• Methylphenidate (generic Ritalin, Concerta): Also first-line on most PDLs. FDA-approved for children age 6 and older; multiple generic formulations keep costs low [12].
• Amphetamine ER (generic Adzenys XR-ODT equivalent): Some Centene plans prefer the orally disintegrating tablet formulation for pediatric patients who cannot swallow capsules.

Non-Stimulant Options Covered on Most Centene Plans

• Atomoxetine (generic Strattera): Non-stimulant, FDA-approved for ADHD in children 6 and older and adults. Available generically since 2017 [13]. Preferred on many Centene Medicaid plans for patients with substance use disorder history or cardiovascular contraindications to stimulants.
• Viloxazine ER (Qelbree): FDA-approved in 2021 for children ages 6 to 17 [14] and in 2022 for adults. Non-stimulant, not a controlled substance. Some Centene marketplace plans cover it at Tier 3 with PA.
• Guanfacine ER (generic Intuniv): Alpha-2 agonist, FDA-approved for ADHD adjunctive therapy in children. Generic availability keeps it at Tier 1 or 2 on most plans [15].

The decision about which medication to prescribe (and which to document as a prior trial for PA purposes) should be made by your prescriber based on your individual symptom profile, cardiovascular history, and history of substance use. The above list reflects formulary positioning, not a clinical recommendation.

MHPAEA and Your Rights as a Centene Member

The Mental Health Parity and Addiction Equity Act, enacted in 2008 and strengthened by the 2024 final rule published by the Departments of Labor, Health and Human Services, and Treasury, requires that non-quantitative treatment limitations (NQTLs) applied to mental health benefits be no more restrictive than those applied to medical/surgical benefits [10].

What This Means Practically

Step therapy for ADHD medications is an NQTL. If Centene requires a patient to fail two generic stimulants before accessing Vyvanse for ADHD, but does not require comparable step therapy for, say, a branded medication for a cardiovascular condition, that asymmetry may violate MHPAEA. The 2024 final rule strengthened enforcement by requiring plans to conduct and document a comparative analysis of NQTLs and make that analysis available to members and regulators on request [10].

If your Centene plan denies Vyvanse under step therapy, you or your prescriber can:

1. Request the plan's NQTL comparative analysis in writing.
2. File a complaint with the Department of Labor's Employee Benefits Security Administration (EBSA) for ERISA-governed employer plans.
3. File a complaint with your state insurance commissioner for individual or fully-insured group plans.
4. Cite MHPAEA in your formal appeal letter.

Pediatric Considerations: Vyvanse Coverage for Children on Centene Plans

Children represent a large share of Vyvanse prescriptions given the ADHD indication starts at age 6. Several Centene Medicaid plans serving children (CHIP and Medicaid) have specific pediatric PA criteria.

Age-Based Coverage Rules

Most Centene plans cover Vyvanse for children ages 6 and older, consistent with the FDA label [2]. Some plans require the diagnosis to be established by a licensed child psychiatrist or developmental pediatrician rather than a primary care provider, particularly on Medicaid plans. If your child's prescriber is a family medicine physician or pediatrician, ask whether the plan requires a specialist note or consultation documentation.

School Performance Documentation

Medicaid PA reviewers often request documentation of school-based functional impairment, such as teacher rating scales (Vanderbilt ADHD Diagnostic Teacher Rating Scale or Conners Rating Scales). Including these forms in the initial PA submission reduces the back-and-forth that delays approval. The 2019 AAP guideline specifically recommends using validated rating scales for diagnosis and monitoring [3], so including them aligns with best-practice standards the plan cannot reasonably dispute.

Checking Your Specific Centene Plan's Current Vyvanse Coverage

Formularies change annually and sometimes mid-year. These are the direct steps to verify Vyvanse coverage right now.

For Ambetter Marketplace Plans

Visit ambetterhealth.com, select your state, log in to the member portal, and search the formulary tool for "lisdexamfetamine" or "Vyvanse." Note the tier, PA requirement, and any quantity limits listed.

For WellCare Medicare Part D Plans

Use the Medicare Plan Finder at medicare.gov to look up your specific WellCare plan and drug coverage. The CMS drug formulary files for all Part D plans are also publicly available at cms.gov, updated quarterly [6].

For Centene Medicaid Plans

Contact your plan's member services number (on your insurance card) and ask the representative to confirm whether lisdexamfetamine dimesylate (brand: Vyvanse) requires prior authorization and what the preferred alternatives are. Request the full formulary or preferred drug list in writing.